<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004390</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0322</org_study_id>
    <nct_id>NCT04004390</nct_id>
  </id_info>
  <brief_title>Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin</brief_title>
  <acronym>PPS and IGIV</acronym>
  <official_title>Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin: a Retrospective Study of Efficacy on Clinical and Isokinetic Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study evaluates the efficacy of IGIV treatment in PPS on clinical (walking and pain) and
      isokinetic (muscle strength) criteria, on patients with PS at Montpellier's Hospital
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are admitted to a multidisciplinary consultation (neurologist, PMK) to validate the
      indication of treatment with IGIV. Realization of a pre-therapeutic evaluation in the
      department of MPR on the criteria of judgment, then the patient is admitted in a service of
      neurology to benefit from the cure of IGIV. The patient is then re-admitted to a PMR service
      for post-treatment evaluation.

      Collection of data retrospectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Muscular strength</measure>
    <time_frame>5 months</time_frame>
    <description>Muscular strength with isokinetic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Walking perimeter</measure>
    <time_frame>5 months</time_frame>
    <description>Walking perimeter with walking test (6 minutes)</description>
  </secondary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Post-Poliomy√©litis Syndrom</condition>
  <eligibility>
    <study_pop>
      <textblock>
        15 men and 11 women with Diagnosis of PPS
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PPS

          -  Pre- and post-therapeutic evaluation carried out

          -  Data transcribed in the computerized patient file

        Exclusion Criteria:

          -  No walking patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MOIZIARD Vincent, intern</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre- and post-therapeutic evaluation carried out</keyword>
  <keyword>Data transcribed in the computerized patient file</keyword>
  <keyword>post-poliomyelitis syndrome</keyword>
  <keyword>Intravenous immunoglobulins</keyword>
  <keyword>walking test</keyword>
  <keyword>isokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
    <mesh_term>Postpoliomyelitis Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

